Covered recipient · General Payments record
BERNARD AZER
General Payments · PY2019–2025
$1,007.32
- Reported across 42 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $461.42 | 16 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Ardelyx, Inc. | $351.56 | 12 |
| AKEBIA THERAPEUTICS INC | $54.58 | 2 |
| CALLIDITAS THERAPEUTICS US INC. | $29.99 | 1 |
| DePuy Synthes Sales Inc. | $25.29 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (16)
Sorted by paying entity, then date · as published by CMS
Program year 2025 201920202021202220232024
Record-level detail is published for PY2025; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC | $27.63 | 02/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1241816316 | CMS |
| AKEBIA THERAPEUTICS INC | $26.95 | 06/09/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1241818510 | CMS |
| Ardelyx, Inc. | $20.60 | 02/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247833293 | CMS |
| Ardelyx, Inc. | $30.00 | 03/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247833295 | CMS |
| Ardelyx, Inc. | $19.16 | 04/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247833297 | CMS |
| Ardelyx, Inc. | $29.21 | 06/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247833299 | CMS |
| Ardelyx, Inc. | $120.09 | 06/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247833301 | CMS |
| Ardelyx, Inc. | $28.11 | 07/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247833303 | CMS |
| Ardelyx, Inc. | $21.26 | 08/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247833305 | CMS |
| Ardelyx, Inc. | $5.60 | 09/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247833307 | CMS |
| Ardelyx, Inc. | $5.33 | 09/15/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247833309 | CMS |
| Ardelyx, Inc. | $22.13 | 10/20/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247833311 | CMS |
| Ardelyx, Inc. | $27.80 | 11/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247833313 | CMS |
| Ardelyx, Inc. | $22.27 | 12/01/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1247833315 | CMS |
| Calliditas Therapeutics US Inc. | $29.99 | 01/30/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234991835 | CMS |
| DePuy Synthes Sales Inc. | $25.29 | 08/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1174073853 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.